AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38971151
Drug: Neoadjuvant monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant monotherapy with the PARP inhibitor (PARPi) niraparib
Trial: 38971151
Drug: Neoadjuvant therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapies
Trial: 38971385
Drug: Personalized response-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized response-based adaptive radiation therapy (RT) with concurrent chemoradiation therapy
Trial: 38971385
Drug: Personalized response-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized response-based adaptive radiation therapy (RT)
Trial: 38971633
Drug: Silicone-based spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone-based spray
Trial: 38971950
Drug: Atezolizumab 1200
RxNorm normalized name: atezolizumab 1200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 1200 mg on Day 1 every 3 weeks
Trial: 38972535
Drug: Post-PCI heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-PCI heparin
Trial: 38972535
Drug: Higher hourly
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher hourly dose or total doses of heparin
Trial: 38972535
Drug: No post-PCI
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No post-PCI heparin
Trial: 38972612
Drug: Nitrate-rich beetroot
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate-rich beetroot juice (400 mg dose)
Trial: 38972612
Drug: Daily consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily consumption of 2 × 400 mg of nitrate over 4 weeks
Trial: 38972831
Drug: Cytoreductive prostatectomy
RxNorm normalized name: GELATIN,ABSORBABLE PROSTATECTOMY CONE,SZ 13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive prostatectomy with systemic therapy
Trial: 38972831
Drug: Cytoreductive prostate
RxNorm normalized name: Sus scrofa prostate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive prostate radiotherapy or ablation with systemic therapy
Trial: 38972831
Drug: Additional cytoreductive
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional cytoreductive treatment
Trial: 38974350
Drug: Parenteral thiamine
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral thiamine (100 mg daily for ≥3 d)
Trial: 38975302
Drug: l-oxiracetam
RxNorm normalized name: oxiracetam
DrugBank: Oxiracetam (DB13601)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-oxiracetam
Trial: 38975711
Drug: L-tyrosine (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tyrosine (2000 mg)
Trial: 38976126
Drug: SB11 Pre-filled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB11 Pre-filled Syringe (PFS) administered at a dosage of 0.5 mg via intravitreal injection (IVT).
Trial: 38976265
Drug: 24-mg dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-mg dose of a weekly extended-release formulation of buprenorphine (CAM2038)
Trial: 38976270
Drug: VMP 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VMP 200 mg twice a day
Trial: 38976270
Drug: VMP 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VMP 200 mg twice a day (twin pregnancies)
Trial: 38976270
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (twin pregnancies)
Trial: 38976363
Drug: Cilofexor 30
RxNorm normalized name: Cilofexor
DrugBank: Cilofexor (DB15168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilofexor 30 mg (weeks 1-4), 60 mg (weeks 5-8), 100 mg (weeks 9-12)
Trial: 38976448
Drug: Zastaprazan 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zastaprazan 20 mg once daily for 8 weeks
Trial: 38976710
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy for 12 weeks
Trial: 38977298
Drug: 4CMenB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4CMenB vaccine (3+1 schedule)
Trial: 38977298
Drug: 4CMenB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4CMenB vaccine (2+1 schedule)
Trial: 38977361
Drug: Brace treatment
RxNorm normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brace treatment with a Pavlik harness for a minimum of 6 weeks
Trial: 38977536
Drug: Doxorubicin for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin for 4 cycles (3 months) followed by trastuzumab adjuvant therapy and 20 mg of oral rosuvastatin once daily for 6 months
Trial: 38977536
Drug: Doxorubicin for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin for 4 cycles (3 months) followed by trastuzumab adjuvant therapy (control group)
Trial: 38977651
Drug: ECAP dose-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECAP dose-controlled closed-loop spinal cord stimulation (SCS)
Trial: 38977983
Drug: Preoperative hyperglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative hyperglycemia (defined as ≥ 6.1mmol/L)
Trial: 38978009
Drug: Multidisciplinary medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary medication review using STOPP criteria
Trial: 38978009
Drug: Multidisciplinary medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary medication review using START criteria
Trial: 38978065
Drug: Universal testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal testing and treatment (UTT) intervention
Trial: 38978089
Drug: Decolonization with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decolonization with octenisan® wash lotion 1× per day and octenisan® md nasal gel 2-3× per day for 5 days
Trial: 38978119
Drug: Fu's subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fu's subcutaneous needling (FSN) therapy, 3 times a week for 2 weeks
Trial: 38978119
Drug: Celecoxib, 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib, 0.2 g/day oral for 2 weeks
Trial: 38978119
Drug: Fu's subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fu's subcutaneous needling (FSN) therapy
Trial: 38978117
Drug: Cardio-Metabolic Clinic
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardio-Metabolic Clinic treatment
Trial: 38978309
Drug: ACE inhibitors/ARBs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors/ARBs use
Trial: 38978354
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin 10%
Trial: 38978405
Drug: CAB+RPV LA
RxNorm normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAB+RPV LA administered every 2 months (Q2M)
Trial: 38978512
Drug: 9vHPV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9vHPV vaccine (second dose administered at enrollment, day 1)
Trial: 38978512
Drug: 9vHPV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9vHPV vaccine (first dose administered ≥1 year before enrollment)
Trial: 38978512
Drug: 9vHPV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9vHPV vaccine (adverse events reported through 15 days after vaccination)
Trial: 38978673
Drug: ICV GD2-CART
RxNorm normalized name: prilocaine
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ICV GD2-CART infusions
Trial: 38979062
Drug: Ceftaroline fosamil
RxNorm normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftaroline fosamil (≥4 consecutive intravenous doses)
Trial: 38979073
Drug: Psychophysical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychophysical therapy (received by 73% of AN participants)
Trial: 38979756
Drug: TAS-303 18
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS-303 18 mg
Trial: 38980511
Drug: Adipose tissue
RxNorm normalized name: Autologous stromal vascular fraction from adipose tissue
DrugBank: Autologous adipose-derived stromal vascular fraction cells (DB18679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adipose tissue injection
Trial: 38980678
Drug: Multilevel interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multilevel interventions including electronic medical record changes and oral health education and skills training
Trial: 38980678
Drug: AAP-based standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAP-based standard oral health education
Trial: 38980676
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) with orteronel, 300 mg orally twice daily
Trial: 38980676
Drug: AD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AD therapy with bicalutamide, 50 mg orally daily
Trial: 38980675
Drug: Internet-based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based Cognitive Behavioral Therapy for Insomnia (eCBT-I) delivered over 6 weekly lesson modules with assigned homework activities.
Trial: 38980710
Drug: Artificial intelligence-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial intelligence-based self-management app (selfBACK) as an adjunct to usual care
Trial: 38980968
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (cholecalciferol, 100,000 IU, five doses in 3 months)
Trial: 38981063
Drug: Previous intravenous
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previous intravenous methotrexate treatment
Trial: 38982000
Drug: Inhaled xenon
RxNorm normalized name: xenon
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled xenon combined with target temperature management (33 °C) for 24 hours
Trial: 38982051
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SOC) chemotherapy
Trial: 38982528
Drug: Once-daily insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily insulin glargine 300 U/mL (Gla-300)
Trial: 38982903
Drug: Treatment modality
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment modality A
Trial: 38982903
Drug: Treatment modality
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment modality B
Trial: 38983151
Drug: Nintedanib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib 200 mg orally twice daily until disease progression or unacceptable toxicity
Trial: 38983158
Drug: Nefopam 20
RxNorm normalized name: nefopam 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam 20 mg administered before surgical incision and at the end of surgery during chest tube insertion.
Trial: 38983158
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 100 mL administered as control.
Trial: 38983729
Drug: Vilaprisan (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilaprisan (4 mg)
Trial: 38983729
Drug: Vilaprisan (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilaprisan (2 mg)
Trial: 38983729
Drug: Vilaprisan (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilaprisan (4 mg and 2 mg)
Trial: 38983736
Drug: Corifollitropin α
RxNorm normalized name: urofollitropin
DrugBank: Urofollitropin (DB00094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corifollitropin α (weekly continuous dosing)
Trial: 38983736
Drug: Daily follicle-stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily follicle-stimulating hormone protocol (control)
Trial: 38984118
Drug: LCD supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCD supplement (lutein 20 mg, zeaxanthin isomers 4 mg, curcumin 200 mg, vitamin D3 600 IU)
Trial: 38984118
Drug: LCD supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCD supplement
Trial: 38985436
Drug: Rimegepant 75
RxNorm normalized name: rimegepant 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimegepant 75 mg, orally, up to once daily for up to 52 weeks
Trial: 38985561
Drug: Rezafungin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rezafungin (400 mg/200 mg once-weekly)
Trial: 38985561
Drug: Caspofungin (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin (70 mg/50 mg once-daily)
Trial: 38985785
Drug: Single-dose azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single-dose azithromycin for 1-5 month-olds during trachoma MDA
Trial: 38985817
Drug: Adherence to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence to post-treatment recommendations
Trial: 38985979
Drug: LIS1 (0.6,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIS1 (0.6, 1, 3, 6, 8, or 10 mg/kg)
Trial: 38985979
Drug: LIS1 (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIS1 (8 mg/kg and 10 mg/kg)
Trial: 38986058
Drug: Nirsevimab therapy
RxNorm normalized name: Nirsevimab
DrugBank: Nirsevimab (DB16258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nirsevimab therapy
Trial: 38986421
Drug: Capmatinib 400
RxNorm normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capmatinib 400 mg bid plus nazartinib 100 mg qd (RP2D)
Trial: 38986421
Drug: Capmatinib 400
RxNorm normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capmatinib 400 mg bid plus nazartinib 100 mg qd (RP2D) in group 1 + phase 1b RP2D
Trial: 38986541
Drug: 0.1 mL
RxNorm normalized name: ethanol 0.1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mL of 24% sucrose administered 2 min prior to painful procedures
Trial: 38986608
Drug: 25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/kg HLX22 + HLX02 + XELOX (group A)
Trial: 38986608
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg HLX22 + HLX02 + XELOX (group B)
Trial: 38986667
Drug: Aldose reductase
RxNorm normalized name: Aldose reductase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldose reductase inhibitor
Trial: 38986791
Drug: Common side
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common side effect treatments (acetaminophen, loperamide, ondansetron)
Trial: 38986891
Drug: Placebo control,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control, mock laser (ML) acupuncture
Trial: 38986891
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (EA and ML)
Trial: 38987228
Drug: Eculizumab (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab (intravenous infusion, once weekly for 4 weeks) with IVIg treatment
Trial: 38987228
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with IVIg treatment
Trial: 38987363
Drug: Regorafenib (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regorafenib (120 or 160 mg daily) given from day 4 to day 10 of each 14-day cycle of FOLFIRINOX (including oxaliplatin, folinic acid, fluorouracil, and irinotecan at 150 or 180 mg/m²)
Trial: 38987421
Drug: AMH ≥
RxNorm normalized name: Anti-Müllerian hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMH ≥ 1.1 ng/mL
Trial: 38987421
Drug: AMH <
RxNorm normalized name: Antimicrobial Handwashing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMH < 1.1 ng/mL
Trial: 38987784
Drug: Coenzyme-Q10 (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coenzyme-Q10 (240 mg daily)
Trial: 38987786
Drug: Combined usage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined usage of povidone-iodine irrigation and topical vancomycin powder before wound closure
Trial: 38988185
Drug: Govorestat 5
RxNorm normalized name: govorestat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Govorestat 5 mg/kg
Trial: 38988185
Drug: Govorestat 20
RxNorm normalized name: govorestat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Govorestat 20 mg/kg
Trial: 38988185
Drug: Govorestat 40
RxNorm normalized name: govorestat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Govorestat 40 mg/kg
Trial: 38988285
Drug: ASC10 (50-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASC10 (50-800 mg, twice daily for 5.5 days)
Trial: 38989287
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (mannan-allergoid conjugates) via subcutaneous (SC) and sublingual (SL) routes at doses of 500, 1,000, 3,000, or 5,000 mTU/mL
Trial: 38989287
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (mannan-allergoid conjugates) via SC
Trial: 38989287
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (mannan-allergoid conjugates) via SL
Trial: 38989414
Drug: PDS01ADC in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDS01ADC in combination with floxuridine delivered via a hepatic artery infusion pump (HAIP)
Trial: 38990016
Drug: GST-HG171; single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GST-HG171; single-dose administration; specific dosage not mentioned.
Trial: 38990016
Drug: Healthy subjects;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy subjects; single-dose administration of GST-HG171; specific dosage not mentioned.
Trial: 38990090
Drug: Dostarlimab with
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dostarlimab with chemotherapy
Trial: 38990250
Drug: Conservative approach
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative approach (optimal medical therapy alone)
Trial: 38990564
Drug: Ultralow-dose radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultralow-dose radiation therapy to 4 Gy in 2 fractions, with an additional 20 Gy in 10 fractions for persistent cases.
Trial: 38990564
Drug: Ultralow-dose radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultralow-dose radiation therapy to 4 Gy in 2 fractions.
Trial: 38990564
Drug: Ultralow-dose radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultralow-dose radiation therapy to 4 Gy in 2 fractions for newly diagnosed, untreated stage I mucosa-associated lymphoid tissue lymphoma.
Trial: 38990638
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive pill (COCP) users (n=20)
Trial: 38990638
Drug: Hormonal implant
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal implant users (n=20)
Trial: 38990638
Drug: Hormonal injection
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal injection users (n=20)
Trial: 38990808
Drug: Social Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social Cognitive Behaviour Treatment (SCBT)
Trial: 38990927
Drug: ILB® (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ILB® (low molecular weight dextran sulphate) administered at a dosage of 2 mg/kg weekly for up to 38 weeks
Trial: 38990927
Drug: ILB® treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ILB® treatment
Trial: 38990927
Drug: Long-term follow-up
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term follow-up after ILB® treatment
Trial: 38991123
Drug: Tipifarnib 300
RxNorm normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tipifarnib 300 mg orally twice daily for 21 days in a 28-day cycle
Trial: 38991137
Drug: Pfizer-BioNTech vaccine
RxNorm normalized name: Pfizer-BioNTech COVID-19 Vaccine
DrugBank: Tozinameran (DB15696)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pfizer-BioNTech vaccine (2 doses)
Trial: 38991216
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with oxygen during acute SARS-CoV-2 infection
Trial: 38991671
Drug: Experiencing medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experiencing medication side effects.
Trial: 38991671
Drug: Contextual factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contextual factors such as frequent changes to prescription and polypharmacy.
Trial: 38991714
Drug: Epidural ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ropivacaine 0.2% + 2 µg/mL epinephrine